Korean J Helicobacter Up Gastrointest Res.  2012 Dec;12(4):219-223. 10.7704/kjhugr.2012.12.4.219.

Recent Trends of Helicobacter pylori Eradication Therapy in Korea

• Kim YK
• Kim JS
• Kim BW

• KMID: 2143406
• DOI: http://doi.org/10.7704/kjhugr.2012.12.4.219

Abstract

Helicobacter pylori infection is one of the most common gastrointestinal infectious diseases in Korea and is related to diseases such as gastritis, peptic ulcer disease, marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type, and gastric adenocarcinoma. The eradication of H. pylori infection requires combinations of antibiotics and acid suppressants. Triple therapy has been considered as the first-line therapy for a long time. However, its eradication rate is declining and we need more effective strategies. Quadruple therapy including acid suppressants, bismuth, and other two antibiotics is a main rescue therapy after first-line therapy failure in Korea. In this review, we describe new therapeutic regimens and new trends of H. pylori eradication in Korea.

Keyword

Helicobacter pylori; Eradication

MeSH Terms

Adenocarcinoma
Anti-Bacterial Agents
Bismuth
Communicable Diseases
Gastritis
Helicobacter
Helicobacter pylori
Korea
Lymphoid Tissue
Lymphoma, B-Cell, Marginal Zone
Peptic Ulcer
Anti-Bacterial Agents
Bismuth